Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.

Fernández-Yunquera A, Ripoll C, Bañares R, Puerto M, Rincón D, Yepes I, Catalina V, Salcedo M.

World J Transplant. 2014 Jun 24;4(2):133-40. doi: 10.5500/wjt.v4.i2.133.

2.

Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.

Manzia TM, Angelico R, Ciano P, Mugweru J, Owusu K, Sforza D, Toti L, Tisone G.

World J Gastroenterol. 2014 Sep 14;20(34):12217-25. doi: 10.3748/wjg.v20.i34.12217.

3.

Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors.

Villamil FG, Gadano AC, Zingale F, Perez R, Gil O, Yantorno S, Mastai R, Cairo FO, Otero AB, Dong G, Lopez P; REVERT Study Group.

Liver Int. 2014 Nov;34(10):1513-21.

PMID:
25453134
4.

Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients.

Alpay N, Ozkok A, Caliskan Y, Akagun T, Cinar SA, Deniz G, Sariyar M, Yildiz A.

Clin Exp Nephrol. 2014 Dec;18(6):961-7. doi: 10.1007/s10157-014-0939-4. Epub 2014 Feb 11.

PMID:
24515306
5.

Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience.

Cholongitas Ε, Goulis I, Theocharidou E, Antoniadis N, Fouzas I, Giakoustidis D, Imvrios G, Giouleme O, Papanikolaou V, Akriviadis E, Vasiliadis T.

Hepatol Int. 2014 Jan;8(1):137-45. doi: 10.1007/s12072-013-9492-6. Epub 2013 Dec 28.

PMID:
26202415
6.

The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection.

Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV.

PLoS One. 2011;6(8):e23218. doi: 10.1371/journal.pone.0023218. Epub 2011 Aug 17.

7.

[Old donors in liver transplantation for chronic hepatitis C].

Aguilera V, Ponce M, Berenguer M, Moreno R, Rayón JM, Sanjuán F, Prieto M, Mir J.

Rev Esp Enferm Dig. 2007 Oct;99(10):581-7. Spanish.

8.

Neutrophil gelatinase-associated lipocalin (NGAL) in heart transplant recipients after conversion to everolimus therapy.

Stypmann J, Fobker M, Rosing K, Engelen M, Gunia S, Dell'Aquila AM, Nofer JR.

J Cardiol. 2015 Oct;66(4):347-52. doi: 10.1016/j.jjcc.2014.12.010. Epub 2015 Jan 9.

9.

Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.

Hüsing A, Schmidt M, Beckebaum S, Cicinnati VR, Koch R, Thölking G, Stella J, Heinzow H, Schmidt HH, Kabar I.

Ann Transplant. 2015 Nov 26;20:707-13.

10.

Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.

Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L; SCHEDULE investigators.

Am J Transplant. 2016 Apr;16(4):1238-47. doi: 10.1111/ajt.13588. Epub 2016 Jan 28.

11.

Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi.

Becker LE, Weritz B, Yi X, Gross-Weissmann ML, Waldherr R, Zeier M, Sommerer C.

Transpl Int. 2015 May;28(5):553-64. doi: 10.1111/tri.12529. Epub 2015 Feb 16.

12.

Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.

Rivelli RF, Gonçalves RT, Leite M Jr, Santos MA, Delgado AG, Cardoso LR, Takiya CM.

Nephrology (Carlton). 2015 Mar;20(3):168-76. doi: 10.1111/nep.12368.

PMID:
25404086
13.

Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.

Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, Gadba R, Tambur AR, Tur-Kaspa R, Mor E.

Cytokine. 2004 Jul 7;27(1):7-14.

PMID:
15207246
14.

Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection.

Sanvisens A, Serra I, Tural C, Tor J, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Muga R.

J Viral Hepat. 2009 Jul;16(7):513-8. doi: 10.1111/j.1365-2893.2009.01103.x. Epub 2009 Feb 5.

PMID:
19200132
15.

Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.

Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD.

World J Gastroenterol. 2015 May 28;21(20):6236-45. doi: 10.3748/wjg.v21.i20.6236.

16.

Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.

De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.

Liver Transpl. 2009 Oct;15(10):1262-9. doi: 10.1002/lt.21827.

17.

Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C.

Pungpapong S, Nunes DP, Krishna M, Nakhleh R, Chambers K, Ghabril M, Dickson RC, Hughes CB, Steers J, Nguyen JH, Keaveny AP.

Liver Transpl. 2008 Sep;14(9):1294-302. doi: 10.1002/lt.21508.

18.

Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C.

Manzia TM, Angelico R, Toti L, Bellini MI, Sforza D, Palmieri G, Orlando G, Tariciotti L, Angelico M, Tisone G.

Transpl Int. 2011 May;24(5):461-8. doi: 10.1111/j.1432-2277.2011.01228.x. Epub 2011 Feb 5.

19.

The role of everolimus in liver transplantation.

Ganschow R, Pollok JM, Jankofsky M, Junge G.

Clin Exp Gastroenterol. 2014 Sep 2;7:329-43. doi: 10.2147/CEG.S41780. eCollection 2014. Review.

20.

Vitamin D deficiency: correlation to interleukin-17, interleukin-23 and PIIINP in hepatitis C virus genotype 4.

Schaalan MF, Mohamed WA, Amin HH.

World J Gastroenterol. 2012 Jul 28;18(28):3738-44. doi: 10.3748/wjg.v18.i28.3738.

Supplemental Content

Support Center